Margaret L MacMillan

Margaret L. MacMillan is a Professor in the Department of Pediatrics at the University of Minnesota Medical School, specializing in Pediatric Blood & Marrow Transplant and Cellular Therapy. She is a leading expert in hematopoietic stem cell transplantation, graft-versus-host disease (GvHD), and Fanconi anemia, with extensive funding from NIH and industry partners. Her research is highly collaborative, involving institutions across the U.S. and internationally.

Research Interests: Dr. MacMillan’s work focuses on improving outcomes in pediatric transplantation, particularly in managing GvHD and genetic disorders like Fanconi anemia. She leads clinical trials in gene therapy and immunomodulation, aiming to reduce transplant-related complications and enhance long-term survival. Her research integrates clinical innovation with patient-centered outcomes.

Publication Trends: Her recent publications (2020–2025) emphasize translational research in GvHD symptom scales, Fanconi anemia gene therapy, infection risks post-transplant, and bleeding prevention in thrombocytopenic patients. These reflect a strong trend toward clinical trials, genetic associations, and patient-reported outcomes in pediatric hematology.

• Scientific Awards: No specific awards are listed in the provided text.

Advising and Grants: Dr. MacMillan serves as Principal Investigator on multiple NIH- and industry-funded grants, including a Phase 2 trial for Fanconi anemia gene therapy and a multicenter study of T-Guard for steroid-refractory GvHD. She collaborates with numerous researchers and mentors junior investigators, though formal advisees are not listed. Her grant portfolio spans from 2003 to 2026, demonstrating sustained research leadership.

Labs and Teams: She is part of the Transplant and Cellular Therapy team at the University of Minnesota, collaborating with experts in immunology, genetics, and oncology. Her team contributes to national consortia like the BMT CTN and works closely with the National Marrow Donor Program.